Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-24
Target enrollment:
Participant gender:
Summary
Phase 1/2a Phase 1 is an open-label, multicenter dose escalation/dose expansion study
designed to assess the safety, tolerability, pharmacokinetics (PK) and antitumor activity of
IMX-110 in combination with Tislelizumab. The recommended Phase 2 dose (RP2D) will be
evaluated in further dose expansion Phase 2a study submitted as an amendment to this Phase 1
protocol during the conduct of the Phase 1 study.